Goodlass: Back in the rhythm - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

MidCapSelect
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Goodlass: Back in the rhythm

Nov 7, 2002

It has been an impressive show by India Inc. in the second quarter of this fiscal year. Improved agricultural output and recovery in industrial sector in the first half has benefited most of the sectors. Paint majors also have a lot to cherish in the recently ended quarter. While Asian Paints posted a 15% rise in topline in 2QFY03, Goodlass Nerolac, the second largest player, also saw its topline increasing by 9% in the same period.

(Rs m) 2QFY02 2QFY03 Change 1HFY02 1HFY03 Change
Sales 1,605 1,755 9.4% 2,861 3,161 10.5%
Other Income 27 22 -16.2% 46 30 -33.9%
Expenditure 1,399 1,517 8.4% 2,543 2,792 9.8%
Operating Profit (EBDIT) 206 238 15.6% 318 370 16.4%
Operating Profit Margin (%) 12.8% 13.6%   11.1% 11.7%  
Interest 13 4 -67.7% 24 9 -61.7%
Depreciation 63 50 -20.0% 118 100 -14.9%
Profit before Tax 157 206 31.2% 222 291 31.0%
Tax 43 66 54.1% 60 92 52.5%
Profit after Tax/(Loss) 115 141 22.7% 162 199 23.0%
Net profit margin (%) 7.2% 8.0%   5.7% 6.3%  
No. of Shares (m) 15.3 15.3   15.3 15.3  
Earnings per share (Rs)* 30.0 36.8   21.2 26.1  
P/E (x)         5.1  
(*annualised)            

To Read the Full Story, Subscribe or Sign In
To Read the Full Story, Subscribe or Sign In


Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

KANSAI NEROLAC SHARE PRICE


Sep 25, 2020 (Close)

TRACK KANSAI NEROLAC

  • Track your investment in KANSAI NEROLAC with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON KANSAI NEROLAC

KANSAI NEROLAC 5-YR ANALYSIS

COMPARE KANSAI NEROLAC WITH

MARKET STATS